September 14, 2023 Dr. Ann Childress, Lead Investigator in Phase 3 CTx-1301-022 study, Discusses Positive Data Shared at 2023 Psych Congress
Source: Psychiatric Times
Cingulate In The News
May 23, 2023 Dr. Shane Schaffer: Life Changing Work that is Worth the Wait
Source: Rounding The Bases With Joel Goldberg
March 31, 2023 Cingulate and Indegene announce agreement for lead ADHD drug - the first of its kind
Source: Outsourcing-Pharma
March 14, 2023 Cingulate partners with Indegene for ADHD therapy
Source: Pharmaceutical Technology
March 14, 2023 Cingulate and Indegene sign agreement for lead ADHD candidate CTx-1301
Source: Express Pharma
March 13, 2023 Cingulate & Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate
Source: Drug Development & Delivery
March 13, 2023 Cingulate signs agreement to market its first drug candidate
Source: Kansas City Business Journal
March 10, 2023 Positive top-line results announced in study of ADHD therapeutic
Source: Healio
March 2, 2023 Positive Top-Line Results Reported for Fed/Fast Study of Novel ADHD Treatment
Source: Psychiatric Times
February 15, 2023 Cingulate Sets Sights On $18bn ADHD Market With Precision Timed-Release Approach
Source: Scrip
February 13, 2023 Could we have an ADHD stimulant medication with once-daily administration and whole-day efficacy?
Source: Labbook Online
January 25, 2023 Trial of ADHD Medication with Fast Onset of Action, Entire Active Day Efficacy Initiated
Source: Psychiatric Times
January 9, 2023 Cingulate begins Phase 3 tests of novel treatment for ADHD
Source: Kansas City Business Journal